Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
WBRT with/without TMZ or Hippocampal Avoidance in Brain Metastases
NCT02832635Phase 2Unknown
- Sponsor
- Sun Yat-sen University
- Start
- Jul 2016
- Primary completion
- Jun 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of temozolomide in brain metastases (4 arms), sponsored by Sun Yat-sen University. Primary endpoint: Change of neurocognitive function at 4 months. Status: unknown.
02
Drugs
temozolomide
03
Conditions
brain metastases
Beyond the preview
Go deeper on NCT02832635.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02832635.